Nuwellis terminated its REVERSE‑HF randomized trial comparing ultrafiltration with IV loop diuretics in hospitalized heart ...

The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

The study revealed that people with these genetic changes were found to be more than twice as likely to develop heart failure ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...